Shock! Biotech raises money
Monday, 30 March, 2009
Melbourne stem cell company Mesoblast has raised $10.81 million through a private placement to existing as well as new and institutional investors.
The money will be used to further the company’s clinical trial programs, including its bone and cartilage regenerative products.
Mesoblast said the placement of 15.02 million shares was oversubscribed.
The money will come as a boost to the company’s cash reserves, which were $9.6 million as at December 31, 2008.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
